The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adjuvant erlotinib versus observation after complete resection of EGFR-mutant NSCLC: Final overall survival results of Alliance A081105.
 
Ramaswamy Govindan
No Relationships to Disclose
 
Sumithra Mandrekar
Consulting or Advisory Role - Harbinger Oncology, Inc
 
David Kozono
Consulting or Advisory Role - AstraZeneca; Exact Sciences; Genentech
 
Jamie Chaft
Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Exact Sciences; Foundation Medicine; Genentech/Roche; Lilly; Merck; Natera; Nuvation Bio; Revolution Medicines
Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Boehringer Ingelheim; Lilly; Merck
 
David Gerber
Stock and Other Ownership Interests - Gilead Sciences; Walgreens
Consulting or Advisory Role - Bayer; Catalyst Pharmaceuticals; Daichi Sankyo; Jazz Pharmaceuticals; Summit Therapeutics; Taiho Oncology
Research Funding - AstraZeneca (Inst); Novocure (Inst)
Patents, Royalties, Other Intellectual Property - Co-founder, Chief Scientific Officer, OncoSeer Diagnostics, LLC; Royalties from Oxford University Press from two books.; UTSD 3352 - US Patent Application 17/045,482 PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY (“Chemokines” and “Cytokines”); UTSD 3352 - US Patent Application 17/045,482 PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY (“Chemokines” and “Cytokines”); UTSD 4153 - US Patent Application 63/386,387 IMMUNOTHERAPY TOXICITY – CELL PHENOTYPES; UTSD 4169 - US Patent Application 63/382,972 BIOMARKERS INCLUDING RNA FOR IMMUNOTHERAPY TOXICITY; UTSD 4169 - US Patent Application 63/382,972 BIOMARKERS INCLUDING RNA FOR IMMUNOTHERAPY TOXICITY; UTSD 4184 - US Patent Application 63/382,257 T CELL TOLERANT FRACTION AS A PREDICTOR OF IMMUNE-RELATED ADVERSE EVENTS; UTSD 4184 - US Patent Application 63/382,257 T CELL TOLERANT FRACTION AS A PREDICTOR OF IMMUNE-RELATED ADVERSE EVENTS; UTSD 4287 – US Patent Application TBD INNATE AND ADAPTIVE IMMUNE FEATURES ASSOCIATED WITH TOXICITIES IN PATIENTS RECEIVING CHECKPOINT INHIBITOR THERAPY
Other Relationship - OncoSeer Diagnostics
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb
 
Jacob Sands
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/UCB Japan; Fosun Pharma; Genentech/Roche; Gilead Sciences; Jazz Pharmaceuticals; Lilly; Merck; Novartis; Pfizer; Sanofi; Summit Therapeutics
Research Funding - Amgen (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca
 
Sharmila Giri
No Relationships to Disclose
 
Gregory Masters
No Relationships to Disclose
 
Joel Neal
Stock and Other Ownership Interests - SecondLook Health
Honoraria - IDEOlogy Health; Medical Educator Consortium; Medscape; MJH Life Sciences; Navya Network Inc; PlatformQ/Medlive CME; Projects in Knowledge; Research to Practice
Consulting or Advisory Role - Abbvie; Amgen; Anheart Therapeutics; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Iovance Biotherapeutics; Janssen Oncology; Lilly; Natera; Novartis; Novocure; Nuvation Bio; Oxford BioTherapeutics; Regeneron; Summit Therapeutics; Taiho Pharmaceutical; Takeda
Research Funding - Adaptimmune (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Nuvalent, Inc.; Revolution Medicines; Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Up To Date - Royalties
 
Michael Constantine
No Relationships to Disclose
 
Lyudmila Bazhenova
Consulting or Advisory Role - Abbvie; Anheart Therapeutics; Bayer; BMS GmbH & Co. KG; Boehringer Ingelheim; Genentech/Roche; Janssen Oncology; Lilly; Merck; Natera; Nuvalent, Inc.; Pfizer; Revolution Medicines; Summit pharmaceuticals; Taiho Oncology
 
Angelina Tan
No Relationships to Disclose
 
Jeffrey Bradley
Employment - University of Pennsylvania Abramson Cancer Center
Honoraria - Mevion Medical Systems
Consulting or Advisory Role - Mevion Medical Systems
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - Genentech; IBA
 
David Gandara
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Foundation Medicine; Genentech (Inst); Guardant Health (Inst); Henlius (Inst); Henlius USA (Inst); Janssen; Merck; Mirati Therapeutics; Novartis; Oncohost (Inst); One Carbon (Inst); Regeneron
 
Karen Kelly
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
 
Suresh Ramalingam
No Relationships to Disclose
 
Geoff Oxnard
Employment - BlossomHill Therapeutics; Foundation Medicine; LOXO at Lilly
Stock and Other Ownership Interests - BlossomHill Therapeutics; Roche
 
Shakun Malik
No Relationships to Disclose
 
Everett Vokes
Stock and Other Ownership Interests - Coordination Pharmaceuticals; McKesson
Honoraria - Ascendis Pharma (I); Guidepoint Inc (I); Vision2Voice (I)
Consulting or Advisory Role - Abbvie; AstraZeneca; BioNTech SE; Boehringer Ingelheim; Day One Therapeutics; Delcath Systems; Eikon; EMD Serono; Foresight Diagnostics; Genmab; GlaxoSmithKline; Marengo Therapeutics; Merus; MJH Life Sciences; Translational Drug Development LLC
Research Funding - Abbvie; Alliance Pharma; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck; Novartis
 
Tom Stinchcombe
Consulting or Advisory Role - Boehringer Ingelheim; Coherus Biosciences; Gilead Sciences; Janssen Oncology; Pfizer; Takeda
Research Funding - Boehringer Ingelheim (Inst); Mirati Therapeutics (Inst); Nuvalent, Inc. (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Pfizer
Other Relationship - Genentech; GlaxoSmithKline; Merck; Pfizer